UNSPSC 51144126: Levamfetamine succinate

This classification denotes a cns stimulant with the molecular formula C9H13N.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier STC9O9MD79, chemically known as butanedioic acid, compd. with (-)-alpha-methylbenzeneethanamine (1:1) but more generally known as levamfetamine succinate, which bears US NIH Compound Identifier 68638. Most nations, for tariff and trade purposes, schedule levamfetamine succinate under HS 29214900 and SITC 51454. As of Q4 2014, LEVAMFETAMINE SUCCINATE remains US FDA's Preferred Term for this commodity.

SMILES: C[C@H](CC1CCCCC1)N.C(CC(=O)O)C(=O)O.

UNSPSC 51144126 Levamfetamine succinate is a Commodity code representing a single active pharmaceutical ingredient; however, the recent state and local opportunities tagged to this code do not reflect procurement of levamfetamine succinate itself. Instead, the opportunities solicited under this code involve broader pharmaceutical and health-system products — naloxone, generic multi-source pharmaceuticals, and over-the-counter products — suggesting a tagging mismatch between the code's nominal scope and actual procurement activity. State and local governments posting under this code are seeking to acquire finished pharmaceutical products, delivery systems, and inventory management solutions rather than a specific pharmaceutical intermediate or raw material. The soliciting bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves establishing supply contracts with manufacturers and authorized wholesalers, with requirements for compliance certifications including Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), electronic data interchange capability, proof of commercial liability and professional liability insurance, and adherence to federal regulations.

Recent activity is concentrated in Florida and the multistate arena. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with the contract carrying a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs rather than to award a specific contract. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (solicitation S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; the contract carries a two-year term with optional extensions and encompasses Oregon and other participating jurisdictions. The code shows minimal recent activity aligned to levamfetamine succinate specifically and warrants clarification with issuing bodies before committing resources to pursuit.